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Sir,
We thank Dr Lopez-Crapez et al 2010 to have taken cue from
our publication (Loupakis et al, 2009) to highlight a really living
matter: what does ‘KRAS-mutated tumor’ mean? Both methodo-
logical and technical issues contribute to make the answer
extremely complex. Two crucial aspects deserve consideration:
(i) many KRAS mutations that occur with low frequencies have
not been included in the post-hoc analyses of large phase III
randomised trials; (ii) mutation-enriched techniques increase the
percentage of KRAS-mutated specimens by about 15%, when
compared with direct sequencing (Marchetti and Gasparetti, 2009).
Recent studies have shown that retrospective experiences are
indispensable starting points to identify promising molecular
tools, that need to be further evaluated in adequate trials and to be,
if appropriate, introduced in clinical practice. To this end, the
example of BRAF mutations, rapidly translated from retrospective
series (Di Nicolantonio et al, 2008) to clinical guidelines (http://
www.nccn.org) despite the inconclusive results of the post-hoc
analysis of CRYSTAL trial (Rougier et al, 2009), is emblematic. It
is, therefore, undeniable that the strength of retrospectively
acquired evidences draws from their reproducibility. Recently
presented data from the broad experience of the European
Consortium, which included 723 retrospectively analysed specimens
(Tejpar and De Roock, 2009), actually strengthen our results about
the negative predictive role of KRAS codon 61 mutations.
On the other hand, more ambiguous findings have been
reported with regard to KRAS A146T mutation, although its
activating power was strongly suggested by in vitro mutagenesis
assays (Feig and Cooper, 1988) and confirmed by mutational
screening analyses, performed on wide series of colorectal cancers
(Edkins et al, 2006). According to data from the European
Consortium, such somatic mutation, found in 13 analysed samples,
was not mutually exclusive with other KRAS activating alterations
and was not clearly linked with lack of response to cetuximab plus
irinotecan, thus raising perplexity about its negative predictive
impact.
Hence, in conclusion, is the comprehensive detection of all
potential KRAS alterations, including those ‘not described before
in any cancer type’, a biologist’s fancy or a clinical necessity?
Probably neither of them. Nowadays, in daily practice, the
definition of ‘KRAS-mutated tumor’ leads physicians to deny to
metastatic colorectal cancer patients a class of efficacious drugs.
Therefore, the relevance of rare or complex KRAS variants, of
which the activating properties and actual predictive power can be
hypothesised, but not clearly stated, should be evaluated with
caution.
The comprehensive analysis of KRAS gene represents, instead,
an inescapable investigational need, with the aim to better
characterise the biology of colorectal cancer and to opportunely
verify the predictive potential of KRAS rare variants.
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